SELLAS Life Sciences Group, Inc. Decrease in Restricted Cash
SELLAS Life Sciences Group, Inc. (SLS) reported Decrease in Restricted Cash of $1.80 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-13.
Discontinued › Notes
us-gaap:DecreaseInRestrictedCash · last filed 2020-03-13
- SELLAS Life Sciences Group, Inc. decrease in restricted cash for the quarter ending 2018-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. decrease in restricted cash for the quarter ending 2018-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. decrease in restricted cash for the quarter ending 2018-06-30 was -$100.00K.
- SELLAS Life Sciences Group, Inc. decrease in restricted cash for the quarter ending 2018-03-31 was $1.90M.
- SELLAS Life Sciences Group, Inc. decrease in restricted cash for fiscal 2018 was $1.80M.
| Period end | Decrease in Restricted Cash 3 month | Decrease in Restricted Cash 6 month | Decrease in Restricted Cash 9 month | Decrease in Restricted Cash 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | -$100.00K derived: sum of 3 quarters · filed 2020-03-13 | $1.80M 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$100.00K derived: sum of 2 quarters · filed 2018-11-14 | $1.80M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $1.80M 10-Q · filed 2018-08-14 | ||
| 2018-03-31 | $1.90M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |